Atrial Fibrillation and Myocardial Infarction: Clinical and Pathogenic Correlations and Impact for the Prognosis
https://doi.org/10.31550/1727-2378-2023-22-8-23-28
Abstract
Aim. To summarize the contemporary literature data on the clinical and pathogenic correlations between atrial fibrillation (AF) and myocardial infarction (MI).
Key points. AF is one of the most common and clinically significant arrhythmias. In patients with MI, this type of arrhythmia is recorded for the first time in 6 % to 21 % of cases. The review discusses the incidence of AF in patients with various forms of coronary heart disease, mechanisms of arrhythmogenesis, and the ways to predict poor outcomes in a group of patients with AF who had a history of MI.
Conclusion. The mechanisms of AF development in patients with MI need better understanding. AF impact on the short-term and long-term prognosis for patients with MI should be studied better, and modern tools for the classification of poor outcome risks should be developed.
About the Authors
E. A. Shishkina
E.A. Vagner Perm State Medical University
Russian Federation
Russian Federation
26 Petropavlovskaya St., Perm, 614000
O. V. Khlynova
E.A. Vagner Perm State Medical University
Russian Federation
Russian Federation
26 Petropavlovskaya St., Perm, 614000
Yu. I. Lebedeva
E.A. Vagner Perm State Medical University
Russian Federation
Russian Federation
26 Petropavlovskaya St., Perm, 614000
E. N. Safarov
E.A. Vagner Perm State Medical University
Russian Federation
Russian Federation
26 Petropavlovskaya St., Perm, 614000
N. A. Naumova
S.G. Sukhanov Federal Centre for Cardiovascular Surgery
Russian Federation
Russian Federation
35 Marshala Zhukova St., Perm, 614013
References
1. Hindricks G., Potpara T., Dagres N., Arbelo E. at al.; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2021;42(5):373–498. DOI: 10.1093/eurheartj/ehaa612
2. Tsao C.W., Aday A.W., Almarzooq Z.I., Alonso A. et al. Heart disease and stroke statistics — 2022 update: a report from the American Heart Association. Circulation. 2022;145(8):e153–639. DOI: 10.1161/CIR.0000000000001052
3. Lippi G., Sanchis-Gomar F., Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int. J. Stroke. 2021;16(2):217–21. Epub. 2020 Jan. 19. DOI: 10.1177/1747493019897870
4. Benjamin E.J., Muntner P., Alonso A., Bittencourt M.S. et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics — 2019 update: a report from the American Heart Association. Circulation. 2019;139(10): e56–28. DOI: 10.1161/CIR.0000000000000659
5. Nielsen J.C., Lin Y.-J., de Oliveira Figueiredo M.J., Shamloo A.S. et al. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population. EP Europace. 2020;22(8):1147–8. DOI: 10.1093/europace/euaa065
6. Patil S., Gonuguntla K., Rojulpote C., Kumar M. et al. Prevalence and determinants of atrial fibrillation-associated in-hospital ischemic stroke in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am. J. Cardiol. 2021;144:1–7. Epub. 2020 Dec. 29. DOI: 10.1016/j.amjcard.2020.12.066
7. Kobalava Z.D., Lazarev P.V. Risk of coronary events in atrial fibrillation. Kardiologiia. 2020;60(1):43–52. (in Russian). DOI: 10.18087/cardio.2020.1.n828
8. Ardashev A.V., Belenkov Yu.N., Matsiukevich M.Ch., Snezhitskiy V.A. Atrial fibrillation and mortality: prognostic factors and direction of prevention. Kardiologiia. 2021;61(2):91–8. (in Russian). DOI: 10.18087/cardio.2021.2.n1348
9. Di Carlo A., Bellino L., Consoli D., Mori F. et al.; National Research Program: Progetto FAI. La Fibrillazione Atriale in Italia. Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project. Europace. 2019;21(10):1468–75. DOI: 10.1093/europace/euz141
10. Mertz V., Cottin Y., Bentounes S.A., Pastier-Debeaumarché J. et al. Prognosis of atrial fibrillation with or without comorbidities: analysis of younger adults from a nationwide database. J. Clin. Med. 2022;11(7):1981. DOI: 10.3390/jcm11071981
11. Andersson T., Magnuson A., Bryngelsson I.-L., Frøbert O. et al. Allcause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995–2008: a Swedish nationwide long-term case-control study. Eur. Heart J. 2013;34(14):1061–7. DOI: 10.1093/eurheartj/ehs469
12. Shlyakhto E.V., Ezhov А.V., Zenin S.А., Koziolova N.А. et al. Clinical portrait of the atrial fibrillation patient in Russian Federation. Data from the global registry GLORIA AF. Russian Journal of Cardiology. 2017;9(149):21–7. (in Russian). DOI: 10.15829/1560-4071-2017-9-138-142
13. Buchta P., Kalarus Z., Mizia-Stec K., Myrda K. et al. De novo and pre-existing atrial fibrillation in acute coronary syndromes: impact on prognosis and cardiovascular events in long-term follow-up. Eur. Heart J. Acute Cardiovasc. Care. 2021;10(10):1129–39. DOI: 10.1093/ehjacc/zuab091
14. Jani B.D., Nicholl B.I., McQueenie R., Connelly D.T. et al. Multimorbidity and co-morbidity in atrial fibrillation and effects on survival: findings from UK Biobank cohort. Europace. 2018;20(FI_3):f329–36. DOI: 10.1093/europace/eux322
15. Belkouche A., Yao H., Putot A., Chagué F. et al. The multifaceted interplay between atrial fibrillation and myocardial infarction: a review. J. Clin. Med. 2021;10(2):198. DOI: 10.3390/jcm10020198
16. Baturina O.A., Andreev D.A., Ananicheva N.A., Gilyarov M.Yu. et al. Prevalence of atrial fibrillation and use of oral antithrombotic therapy in patients with acute coronary syndrome. Kardiologiia. 2019;59(1):40–8. (in Russian)]. DOI: 10.18087/cardio.2019.1.10213
17. Guenancia Ch., Toucas C., Fauchier L., Stamboul K. et al. High rate of recurrence at long-term follow-up after new-onset atrial fibrillation during acute myocardial infarction. Europace. 2018;20(12): e179–88. DOI: 10.1093/europace/euy168
18. Pokorney S.D., Navar A.M. In patients with MI, new-onset or existing AF increased risk for CV events at 90 days. Ann. Intern. Med. 2016;164(12):JC66. DOI: 10.7326/ACPJC-2016-164-12-066
19. Soliman E.Z., Lopez F., O'Neal W.T., Chen L.Y. et al. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2015;131(21):1843–50. DOI: 10.1161/CIRCULATIONAHA.114.014145
20. Soliman E.Z., Safford M.M., Muntner P., Khodneva Yu. et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern. Med. 2014;174(1):107–14. DOI: 10.1001/jamainternmed.2013.11912
21. Liang F., Wang Y. Coronary heart disease and atrial fibrillation: a vicious cycle. Am. J. Physiol. Heart Circ. Physiol. 2021;320(1): H1–12. Epub. 2020 Nov. 13. DOI: 10.1152/ajpheart.00702.2020
22. Börschel C.S., Schnabel R.B. The imminent epidemic of atrial fibrillation and its concomitant diseases — Myocardial infarction and heart failure — A cause for concern. Int. J. Cardiol. 2019:287: 162–73. Epub. 2018 Nov. 30. DOI: 10.1016/j.ijcard.2018.11.123
23. Putot A., Monin A., Belkouche A., Chagué F. et al. Preexisting atrial fibrillation and myocardial infarction: only 10% of infarcts directly linked to atrial fibrillation. Cardiovasc. Endocrinol. Metab. 2022;11(3):e0267. DOI: 10.1097/XCE.0000000000000267
24. Shiyovich A., Axelrod M., Gilutz H., Plakht Y. Early versus late newonset atrial fibrillation in acute myocardial infarction: differences in clinical characteristics and predictors. Angiology. 2019;70(10): 921–8. DOI: 10.1177/0003319719867542
25. Batra G., Svennblad B., Held C., Jernberg T. et al. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart. 2016;102(12):926–33. DOI: 10.1136/heartjnl-2015-308678
26. Maagh P., Butz T., Wickenbrock I., Prull M.W. et al. New-onset versus chronic atrial fibrillation in acute myocardial infarction: differences in short- and long-term follow-up. Clin. Res. Cardiol. 2011;100(2): 167–75. Epub. 2010 Sep. 23. DOI: 10.1007/s00392-010-0227-6
27. Dai Y., Yang J., Gao Z., Xu H. et al.; CAMI Registry study group. Atrial fibrillation in patients hospitalized with acute myocardial infarction: analysis of the china acute myocardial infarction (CAMI) registry. BMC Cardiovasc. Disord. 2017;17(1):2. DOI: 10.1186/s12872-016-0442-9
28. Kornej J., Henger S., Seewöster T., Teren A. et al. Prevalence of atrial fibrillation dependent on coronary artery status: insights from the LIFE-Heart study. Clin. Cardiol. 2020;43(12):1616–23. DOI: 10.1002/clc.23490
29. El-Shetry M., Mahfouz R., Frere A.-F., Abdeldayem M. The interplay between atrial fibrillation and acute myocardial infarction. Br. J. Hosp. Med. (Lond.). 2021;82(2):1–9. DOI: 10.12968/hmed.2020.0584
30. He J., Yang Y., Zhang G., Lu X.-H. Clinical risk factors for new-onset atrial fibrillation in acute myocardial infarction: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(26):e15960. DOI: 10.1097/MD.0000000000015960
31. Pizzetti F., Turazza F.M., Franzosi M.G., Barlera S. et al.; GISSI-3 Investigators. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart. 2001;86(5):527–32. DOI: 10.1136/heart.86.5.527
32. Vermond R.A., Van Gelder I.C., Crijns H.J., Rienstra M. Does myocardial infarction beget atrial fibrillation and atrial fibrillation beget myocardial infarction? Circulation. 2015;131(21):1824–6. DOI: 10.1161/CIRCULATIONAHA.115.016595
33. Sinno H., Derakhchan K., Libersan D., Merhi Y. et al. Atrial ischemia promotes atrial fibrillation in dogs. Circulation. 2003;107(14): 1930–6. DOI: 10.1161/01.CIR.0000058743.15215.03
34. Broch K., Anstensrud A.K., Woxholt S., Sharma K. et al. Randomized trial of Interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 2021;77(15): 1845–55. DOI: 10.1016/j.jacc.2021.02.049
35. Cheng W.-L., Chen Y.-C., Li S.-J., Lee T.-I. et al. Galectin-3 enhances atrial remodelling and arrhythmogenesis through CD98 signalling. Acta Physiol. (Oxf.). 2022;234(3):e13784. DOI: 10.1111/apha.13784
36. Martins G.L., Duarte R.C.F., Vieira É.L.M., Rocha N.P. et al. Evaluation of new potential inflammatory markers in patients with nonvalvular atrial fibrillation. Int. J. Mol. Sci. 2023;24(4):3326. DOI: 10.3390/ijms24043326
37. Hofer F., Kazem N., Hammer A., El-Hamid F. et al. Long-term prognosis of de novo atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategies. Eur. Heart J. Cardiovasc. Pharmacother. 2021;7(3):189–95. DOI: 10.1093/ehjcvp/pvaa027
38. Solovieva M.V., Boldueva S.A. Prognostic value of atrial fibrillation in patients with myocardial infarction. Long-term follow-up results. Russian Journal of Cardiology. 2021;26(2):4285. (in Russian). DOI: 10.15829/1560-4071-2021-4285
39. Borodashkina S.Y., Protasov K.V. Clinical and pathogenetic features of myocardial infarction in patients with atrial fibrillation. Siberian Medical Review. 2020;5:31–9. (in Russian). DOI: 10.20333/2500136-2020-5-31-39
40. Jabre P., Roger V.L., Murad M.H., Chamberlain A.M. et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and metaanalysis. Circulation. 2011;123(15):1587–93. DOI: 10.1161/CIRCULATIONAHA.110.986661
41. Zeymer U., Annemans L., Danchin N., Pocock S. et al. Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry. Eur. Heart J. Acute Cardiovasc. Care. 2019;8(2):121–9. Epub. 2018 Apr. 3. DOI: 10.1177/2048872618769057
42. Zykov M.V., Barbarash O.L. Pathogenetic and clinical aspects of atrial fibrillation in myocardial infarction. Russian Journal of Cardiology. 2021;26(2):4307. (in Russian). DOI: 10.15829/1560-4071-2021-4307
43. Congo K.H., Belo A., Carvalho J., Neves D. et al. New-onset atrial fibrillation in ST-segment elevation myocardial infarction: predictors and impact on therapy and mortality. Arq. Bras. Cardiol. 2019;113(5): 948–57. DOI: 10.5935/abc.20190190
44. Guo T., Xi Z., Qiu H., Wang Y. et al. Prognostic value of GRACE and CHA2DS2-VASc score among patients with atrial fibrillation undergoing percutaneous coronary intervention. Ann. Med. 2021;53(1):2215–24. DOI: 10.1080/07853890.2021.2004321
45. Greco A., Capodanno D. Therapeutic uncertainties: first finding of atrial fibrillation in acute coronary syndrome. Eur. Heart J. Suppl. 2022;24(Suppl. I):I43–6. DOI: 10.1093/eurheartjsupp/suac072
46. Petersen J.K., Butt J.H., Yafasova A., Torp-Pedersen C. et al. Incidence of ischaemic stroke and mortality in patients with acute coronary syndrome and first-time detected atrial fibrillation: a nationwide study. Eur. Heart J. 2021;42(44):4553–61. DOI: 10.1093/eurheartj/ehab575
47. Zeymer U., Annemans L., Danchin N., Pocock S. et al. Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry. Eur. Heart J. Acute Cardiovasc. Care. 2019;8(2):121–9. Epub. 2018 Apr. 3. DOI: 10.1177/2048872618769057
48. Angeli F., Reboldi G., Garofoli M., Ramundo E. et al. Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. Curr. Cardiol. Rep. 2012;14(5):601–10. DOI: 10.1007/s11886-012-0289-3
49. Kundu A., O’Day K., Shaikh A.Y., Lessard D.M. et al. Relation of atrial fibrillation in acute myocardial infarction to in-hospital complications and early hospital readmission. Am. J. Cardiol. 2016;117(8):1213–8. DOI: 10.1016/j.amjcard.2016.01.012
50. Biasco L., Radovanovic D., Moccetti M., Rickli H. et al. New-onset or preexisting atrial fibrillation in acute coronary syndromes: two distinct phenomena with a similar prognosis. Rev. Esp. Cardiol. 2019;72(5): 383–91. Epub. 2018 Apr. 10. DOI: 10.1016/j.rec.2018.03.002
Review
For citations:
Shishkina E.A., Khlynova O.V., Lebedeva Yu.I., Safarov E.N., Naumova N.A. Atrial Fibrillation and Myocardial Infarction: Clinical and Pathogenic Correlations and Impact for the Prognosis. Title. 2023;22(8):23-28. (In Russ.) https://doi.org/10.31550/1727-2378-2023-22-8-23-28
Views:
15
Email this article 